medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2024-540medsovet-8771Research ArticleЭНДОКРИНОЛОГИЯENDOCRINOLOGYСовременные возможности профилактики и коррекции нарушений углеводного обменаCurrent opportunities for the prevention and treatment of carbohydrate metabolism disordershttps://orcid.org/0000-0003-3494-8011ЗиловА. В.ZilovA. V.

Зилов Алексей Вадимович - к.м.н., доцент кафедры эндокринологии №1 Института клинической медицины имени Н.В. Склифосовского.

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Alexey V. Zilov - Cand. Sci. (Med.), Associate Professor of the Department of Endocrinology No. 1, Sklifosovsky Institute of Clinical Medicine.

8, Bldg. 2, Trubetskaya St., Moscow, 119991

avzilov@hotmail.comhttps://orcid.org/0000-0002-1820-7726БолиеваЛ. З.BolievaL. Z.

Болиева Лаура Зелимхановна - д.м.н., профессор, заслуженный врач Республики Северная Осетия – Алания, главный внештатный специалист – пульмонолог, аллерголог-иммунолог Министерства здравоохранения Республики Северная Осетия – Алания, заведующая кафедрой фармакологии с клинической фармакологией.

362019, Республика Северная Осетия – Алания, Владикавказ, ул. Пушкинская, д. 40

Laura Z. Bolieva - Dr. Sci. (Med.), Professor, Honored Doctor of the Republic of North Ossetia – Alania, Chief Freelance Specialist – Pulmonologist, Allergist-Immunologist of the Ministry of Health of the Republic of North Ossetia – Alania, Head of the Department of Pharmacology with Clinical Pharmacology.

40, Pushkinskaya St., Vladikavkaz, Republic of North Ossetia – Alania, 362019

bolievalz@mail.ruПервый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian FederationСеверо-Осетинская государственная медицинская академияРоссияNorth Ossetian State Medical AcademyRussian Federation202422012025023144150Copyright © Зилов А.В., Болиева Л.З., 20242024Зилов А.В., Болиева Л.З.Zilov A.V., Bolieva L.Z.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/8771

Сахарный диабет представляет собой реальную угрозу жизни и здоровью населения всего мира. В связи с этим чрезвычайно актуальным представляется вопрос о своевременном выявлении людей из групп риска и профилактике развития заболевания. Увеличение физической активности, снижение массы тела, отказ от курения являются эффективными средствами профилактики сахарного диабета 2-го типа. В случае неэффективности мероприятий по изменению образа жизни назначается медикаментозная сахароснижающая терапия. В арсенале эндокринолога и терапевта преобладают препараты, преимущественно оказывающие влияние на гипергликемию. Метформин служит препаратом 1-й линии терапии нарушений углеводного обмена. Известно, что инсулинорезистентность – основная причина развития и прогрессирования осложнений сахарного диабета. Коррекция инсулинорезистентности является эффективной патогенетической медикаментозной тактикой. Однако выбор препарата для этих целей в настоящее время ограничен. В последнее десятилетие разрабатываются новые перспективные препараты, способные повышать чувствительность тканей к инсулину. Субетта – оригинальный отечественный инсулиносенситайзер, способствующий усилению инсулинзависимого метаболизма глюкозы. Это комбинированный препарат, повышающий чувствительность тканей к инсулину, нормализующий функцию эндотелия сосудов, а также способствующий повышению уровня адипонектина. В клинических исследованиях установлено снижение параметров гликемии, снижение индекса инсулинорезистентности, стабилизации массы тела. Целесообразно проведение всероссийской наблюдательной неинтервенционной программы изучения эффективности препарата Субетта в условиях реальной клинической практики у пациентов с предиабетом или сахарным диабетом 2-го типа (СИЛА). В программу включаются данные около 2 500 пациентов старше 18 лет. По результатам программы оценивается эффективность комбинированной терапии сахароснижающими препаратами и препаратом Субетта на основании результатов динамики клинических и лабораторных показателей, опросников для оценки качества жизни.

Diabetes mellitus poses a significant threat to the health and lives of people worldwide. Consequently, the timely identification of individuals at risk and the prevention of disease development are of utmost importance. Increasing physical activity, reducing body weight, and quitting smoking are effective measures for preventing type 2 diabetes. When lifestyle modifications are insufficient, pharmacological glucose-lowering therapy is prescribed. The endocrinologist’s arsenal is dominated by drugs that have a predominant effect on hyperglycemia. Metformin is the 1st line of therapy for disorders of carbohydrate metabolism. It is known that insulin resistance is the main cause of the development and progression of complications of diabetes mellitus. Correction of insulin resistance looks like a promising drug tactic. However, the choice of a drug for these purposes is currently limited. Currently, new, promising drugs are being developed that can increase tissue sensitivity to insulin. Subetta is an original insulin sensitizer that helps to enhance insulin-dependent glucose metabolism. This is a complex drug that increases the sensitivity of tissues to insulin, and normalizes the function of the vascular endothelium, as well as helps to increase the level of adiponectin. A decrease in glycemic parameters, a reduction of the insulin resistance index (HOMA-index) and weight stabilization has been shown in the clinical studies. All-Russian observational non-interventional study is planned to assess the effectiveness of Subetta in real-world clinical practice for patients with prediabetes or type 2 diabetes (SILA). The study includes data from 2,500 patients approximately over the age of 18. The findings of this programme enable a comprehensive evaluation of the effectiveness of combined glucose-lowering therapy in conjunction with Subetta, based on the dynamic assessment of both clinical and laboratory parameters, as well as quality of life questionnaires.

предиабетсахарный диабет 2-го типаинсулинорезистентностьинсулиносенситайзернаблюдательная программаpre-diabetestype 2 diabetesinsulin sensitizerinsulin resistanceobservational studyReferencesIsmail L, Materwala H, Al Kaabi J. Association of risk factors with type 2 diabetes: A systematic review. Comput Struct Biotechnol J. 2021;19:1759–1785. https://doi.org/10.1016/j.csbj.2021.03.003.Ismail L, Materwala H, Al Kaabi J. Association of risk factors with type 2 diabetes: A systematic review. Comput Struct Biotechnol J. 2021;19:1759–1785. https://doi.org/10.1016/j.csbj.2021.03.003.GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–234. https://doi.org/10.1016/S0140-6736(23)01301-6.GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–234. https://doi.org/10.1016/S0140-6736(23)01301-6.Hostalek U. Global epidemiology of prediabetes – present and future perspectives. Clin Diabetes Endocrinol. 2019;5:5. https://doi.org/10.1186/s40842-019-0080-0.Hostalek U. Global epidemiology of prediabetes – present and future perspectives. Clin Diabetes Endocrinol. 2019;5:5. https://doi.org/10.1186/s40842-019-0080-0.Rooney MR, Fang M, Ogurtsova K, Ozkan B, Echouffo-Tcheugui JB, Boyko EJ et al. Global Prevalence of Prediabetes. Diabetes Care. 2023;46(7):1388–1394. https://doi.org/10.2337/dc22-2376.Rooney MR, Fang M, Ogurtsova K, Ozkan B, Echouffo-Tcheugui JB, Boyko EJ et al. Global Prevalence of Prediabetes. Diabetes Care. 2023;46(7):1388–1394. https://doi.org/10.2337/dc22-2376.Драпкина ОМ, Дроздова ЛЮ, Шепель РН, Раковская ЮС, Самойлов ТВ, Жидкова ЕА и др. Анализ распространенности предиабета и реальная клиническая практика назначения медикаментозной терапии пациентам с предиабетом. Профилактическая медицина. 2022;25(12):96–105. https://doi.org/10.17116/profmed20222512196.Drapkina OM, Drozdova LYu, Shepel RN, Rakovskaya YuS, Samoilov TV, Zhidkova EA et al. Analysis of prediabetes prevalence and real-world practice in prescribing drug therapy to prediabetic patients. Profilakticheskaya Meditsina. 2022;25(12):96–105. (In Russ.) https://doi.org/10.17116/profmed20222512196.Matoori S. Diabetes and its Complications. ACS Pharmacol Transl Sci. 2022;5(8):513–515. https://doi.org/10.1021/acsptsci.2c00122.Matoori S. Diabetes and its Complications. ACS Pharmacol Transl Sci. 2022;5(8):513–515. https://doi.org/10.1021/acsptsci.2c00122.Farmaki P, Damaskos C, Garmpis N, Garmpi A, Savvanis S, Diamantis E. Complications of the Type 2 Diabetes Mellitus. Curr Cardiol Rev. 2020;16(4):249–251. https://doi.org/10.2174/1573403X1604201229115531.Farmaki P, Damaskos C, Garmpis N, Garmpi A, Savvanis S, Diamantis E. Complications of the Type 2 Diabetes Mellitus. Curr Cardiol Rev. 2020;16(4):249–251. https://doi.org/10.2174/1573403X1604201229115531.American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes–2019. Diabetes Care. 2019;42(Suppl. 1): S13–S28. https://doi.org/10.2337/dc19-S002.American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes–2019. Diabetes Care. 2019;42(Suppl. 1): S13–S28. https://doi.org/10.2337/dc19-S002.Дедов ИИ, Шестакова МВ, Майоров АЮ, Мокрышева НГ, Андреева ЕН, Безлепкина ОБ и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2023;26(2S):1–157. https://doi.org/10.14341/DM13042.Dedov I, Shestakova M, Mayorov A, Mokrysheva N, Andreeva E, Bezlepkina O et al. Standards of Specialized Diabetes Care. Diabetes Mellitus. 2023;26(2S):1–157. (In Russ.) https://doi.org/10.14341/DM13042.Majety P, Lozada Orquera FA, Edem D, Hamdy O. Pharmacological approaches to the prevention of type 2 diabetes mellitus. Front Endocrinol. 2023;14:1118848. https://doi.org/10.3389/fendo.2023.1118848.Majety P, Lozada Orquera FA, Edem D, Hamdy O. Pharmacological approaches to the prevention of type 2 diabetes mellitus. Front Endocrinol. 2023;14:1118848. https://doi.org/10.3389/fendo.2023.1118848.Packer M. Potentiation of Insulin Signaling Contributes to Heart Failure in Type 2 Diabetes: A Hypothesis Supported by Both Mechanistic Studies and Clinical Trials. JACC Basic Transl Sci. 2018;3(3):415–419. https://doi.org/10.1016/j.jacbts.2018.04.003.Packer M. Potentiation of Insulin Signaling Contributes to Heart Failure in Type 2 Diabetes: A Hypothesis Supported by Both Mechanistic Studies and Clinical Trials. JACC Basic Transl Sci. 2018;3(3):415–419. https://doi.org/10.1016/j.jacbts.2018.04.003.Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, FernándezFernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr. 2019;13(2):1449–1455. https://doi.org/10.1016/j.dsx.2019.02.023.Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, FernándezFernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr. 2019;13(2):1449–1455. https://doi.org/10.1016/j.dsx.2019.02.023.Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF et al. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Int J Obes. 2008;32(10):1537–1544. https://doi.org/10.1038/ijo.2008.134.Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF et al. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Int J Obes. 2008;32(10):1537–1544. https://doi.org/10.1038/ijo.2008.134.Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85–96. https://doi.org/10.1038/nrm1837.Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85–96. https://doi.org/10.1038/nrm1837.Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. https://doi.org/10.1056/NEJMoa0802743.Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. https://doi.org/10.1056/NEJMoa0802743.Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–192. https://doi.org/10.2337/dc08-9026.Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–192. https://doi.org/10.2337/dc08-9026.O’Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N et al. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. JAMA Netw Open. 2018;1(8):e186125. https://doi.org/10.1001/jamanetworkopen.2018.6125.O’Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N et al. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. JAMA Netw Open. 2018;1(8):e186125. https://doi.org/10.1001/jamanetworkopen.2018.6125.Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care. 2009;32(2):361–366. https://doi.org/10.2337/dc08-0854.Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care. 2009;32(2):361–366. https://doi.org/10.2337/dc08-0854.Nyström T, Holzmann MJ, Eliasson B, Svensson AM, Sartipy U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab. 2018;20(3):556–563. https://doi.org/10.1111/dom.13110.Nyström T, Holzmann MJ, Eliasson B, Svensson AM, Sartipy U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab. 2018;20(3):556–563. https://doi.org/10.1111/dom.13110.Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7(6):452–461. https://doi.org/10.1016/S2213-8587(19)30093-2.Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7(6):452–461. https://doi.org/10.1016/S2213-8587(19)30093-2.Bahari NI, Ahmad N, Mahmud MH, Baharom M, Amir SM, Peng CS et al. Issues and Challenges in the Primary Prevention of Type 2 Diabetes Mellitus: A Systematic Review. J Prev. 2023;44(1):105–125. https://doi.org/10.1007/s10935-022-00707-x.Bahari NI, Ahmad N, Mahmud MH, Baharom M, Amir SM, Peng CS et al. Issues and Challenges in the Primary Prevention of Type 2 Diabetes Mellitus: A Systematic Review. J Prev. 2023;44(1):105–125. https://doi.org/10.1007/s10935-022-00707-x.Aroda VR, Ratner RE. Metformin and Type 2 Diabetes Prevention. Diabetes Spectr. 2018;31(4):336–342. https://doi.org/10.2337/ds18-0020.Aroda VR, Ratner RE. Metformin and Type 2 Diabetes Prevention. Diabetes Spectr. 2018;31(4):336–342. https://doi.org/10.2337/ds18-0020.Hostalek U, Campbell I. Metformin for diabetes prevention: update of the evidence base. Curr Med Res Opin. 2021;37(10):1705–1717. https://doi.org/10.1080/03007995.2021.1955667.Hostalek U, Campbell I. Metformin for diabetes prevention: update of the evidence base. Curr Med Res Opin. 2021;37(10):1705–1717. https://doi.org/10.1080/03007995.2021.1955667.Patel D, Ayesha IE, Monson NR, Klair N, Patel U, Saxena A, Hamid P. The Effectiveness of Metformin in Diabetes Prevention: A Systematic Review and Meta-Analysis. Cureus. 2023;15(9):e46108. https://doi.org/10.7759/cureus.46108.Patel D, Ayesha IE, Monson NR, Klair N, Patel U, Saxena A, Hamid P. The Effectiveness of Metformin in Diabetes Prevention: A Systematic Review and Meta-Analysis. Cureus. 2023;15(9):e46108. https://doi.org/10.7759/cureus.46108.Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, Haque M. Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. Drug Des Devel Ther. 2023;17:1907–1932. https://doi.org/10.2147/DDDT.S409373.Dutta S, Shah RB, Singhal S, Dutta SB, Bansal S, Sinha S, Haque M. Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. Drug Des Devel Ther. 2023;17:1907–1932. https://doi.org/10.2147/DDDT.S409373.Goldberg RB, Orchard TJ, Crandall JP, Boyko EJ, Budoff M, Dabelea D et al. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. Circulation. 2022;145(22):1632–1641. https://doi.org/10.1161/CIRCULATIONAHA.121.056756.Goldberg RB, Orchard TJ, Crandall JP, Boyko EJ, Budoff M, Dabelea D et al. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. Circulation. 2022;145(22):1632–1641. https://doi.org/10.1161/CIRCULATIONAHA.121.056756.Madsen KS, Chi Y, Metzendorf MI, Richter B, Hemmingsen B. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019;12(12):CD008558. https://doi.org/10.1002/14651858.CD008558.pub2.Madsen KS, Chi Y, Metzendorf MI, Richter B, Hemmingsen B. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019;12(12):CD008558. https://doi.org/10.1002/14651858.CD008558.pub2.Chen Y, Ma H, Zhu D, Zhao G, Wang L, Fu X, Chen W. Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets. PPAR Res. 2017;2017:8360919. https://doi.org/10.1155/2017/8360919.Chen Y, Ma H, Zhu D, Zhao G, Wang L, Fu X, Chen W. Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets. PPAR Res. 2017;2017:8360919. https://doi.org/10.1155/2017/8360919.Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996;19(2):151–156. https://doi.org/10.2337/diacare.19.2.151.Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996;19(2):151–156. https://doi.org/10.2337/diacare.19.2.151.Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001;56:265–294. https://doi.org/10.1210/rp.56.1.265.Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001;56:265–294. https://doi.org/10.1210/rp.56.1.265.Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician. 2001;63(9):1747–1756. Available at: https://www.aafp.org/pubs/afp/issues/2001/0501/p1747.html.Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician. 2001;63(9):1747–1756. Available at: https://www.aafp.org/pubs/afp/issues/2001/0501/p1747.html.Drazen JM, Morrissey S, Curfman GD. Rosiglitazone – continued uncertainty about safety. N Engl J Med. 2007;357(1):63–64. https://doi.org/10.1056/NEJMe078118.Drazen JM, Morrissey S, Curfman GD. Rosiglitazone – continued uncertainty about safety. N Engl J Med. 2007;357(1):63–64. https://doi.org/10.1056/NEJMe078118.Aghamohammadzadeh N, Niafar M, Dalir Abdolahinia E, Najafipour F, Mohamadzadeh Gharebaghi S, Adabi K et al. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients. Ther Adv Endocrinol Metab. 2015;6(2):56–60. https://doi.org/10.1177/2042018815574229.Aghamohammadzadeh N, Niafar M, Dalir Abdolahinia E, Najafipour F, Mohamadzadeh Gharebaghi S, Adabi K et al. The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients. Ther Adv Endocrinol Metab. 2015;6(2):56–60. https://doi.org/10.1177/2042018815574229.Ghadge AA, Khaire AA, Kuvalekar AA. Adiponectin: A potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev. 2018;39:151–158. https://doi.org/10.1016/j.cytogfr.2018.01.004.Ghadge AA, Khaire AA, Kuvalekar AA. Adiponectin: A potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev. 2018;39:151–158. https://doi.org/10.1016/j.cytogfr.2018.01.004.Crombez D, Delcambre S, Nonclercq D, Vander Elst L, Laurent S, Cnop M et al. Modulation of adiponectin receptors AdipoR1 and AdipoR2 by phage display-derived peptides in in vitro and in vivo models. J Drug Target. 2020;28(7-8):831–851. https://doi.org/10.1080/1061186X.2019.1710840.Crombez D, Delcambre S, Nonclercq D, Vander Elst L, Laurent S, Cnop M et al. Modulation of adiponectin receptors AdipoR1 and AdipoR2 by phage display-derived peptides in in vitro and in vivo models. J Drug Target. 2020;28(7-8):831–851. https://doi.org/10.1080/1061186X.2019.1710840.Yanai H, Yoshida H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int J Mol Sci. 2019;20(5):1190. https://doi.org/10.3390/ijms20051190.Yanai H, Yoshida H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int J Mol Sci. 2019;20(5):1190. https://doi.org/10.3390/ijms20051190.Gorbunov EA, Nicoll J, Kachaeva EV, Tarasov SA, Epstein OI. Subetta increases phosphorylation of insulin receptor β-subunit alone and in the presence of insulin. Nutr Diabetes. 2015;5(7):e169. https://doi.org/10.1038/nutd.2015.20.Gorbunov EA, Nicoll J, Kachaeva EV, Tarasov SA, Epstein OI. Subetta increases phosphorylation of insulin receptor β-subunit alone and in the presence of insulin. Nutr Diabetes. 2015;5(7):e169. https://doi.org/10.1038/ nutd.2015.20.Gorbunov EA, Nicoll J, Myslivets AA, Kachaeva EV, Tarasov SA. Subetta Enhances Sensitivity of Human Muscle Cells to Insulin. Bull Exp Biol Med. 2015;159(4):463–465. https://doi.org/10.1007/s10517-015-2992-8.Gorbunov EA, Nicoll J, Myslivets AA, Kachaeva EV, Tarasov SA. Subetta Enhances Sensitivity of Human Muscle Cells to Insulin. Bull Exp Biol Med. 2015;159(4):463–465. https://doi.org/10.1007/s10517-015-2992-8.Nicoll J, Gorbunov EA, Tarasov SA, Epstein OI. Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro. Int J Endocrinol. 2013;2013:925874. https://doi.org/10.1155/2013/925874.Nicoll J, Gorbunov EA, Tarasov SA, Epstein OI. Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro. Int J Endocrinol. 2013;2013:925874. https://doi.org/10.1155/2013/925874.Mkrtumyan A, Ametov A, Demidova T, Volkova A, Dudinskaya E, Vertkin A, Vorobiev S. A New Approach to Overcome Insulin Resistance in Patients with Impaired Glucose Tolerance: The Results of a Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety of Subetta. J Clin Med. 2022;11(5):1390. https://doi.org/10.3390/jcm11051390.Mkrtumyan A, Ametov A, Demidova T, Volkova A, Dudinskaya E, Vertkin A, Vorobiev S. A New Approach to Overcome Insulin Resistance in Patients with Impaired Glucose Tolerance: The Results of a Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Efficacy and Safety of Subetta. J Clin Med. 2022;11(5):1390. https://doi.org/10.3390/jcm11051390.Мкртумян АМ. Сравнительный анализ эффективности препаратов для лечения ранних нарушений углеводного обмена (предиабета). Терапевтический архив. 2024;96(4):419–428. https://doi.org/10.26442/00403660.2024.04.202709.Mkrtumyan AM. Comparative analysis of the drugs efficacy for carbohydrate metabolism early disorders (prediabetes) treatment: A review. Terapevticheskii Arkhiv. 2024;96(4):419–428. (In Russ.) https://doi.org/10.26442/00403660.2024.04.202709.Мкртумян АМ, Воробьев СВ, Волкова АР, Ворохобина НВ. Влияние препарата Субетта на гликемический контроль у пациентов с сахарным диабетом 2 типа: результаты многоцентрового двойного слепого плацебоконтролируемого рандомизированного клинического исследования. Фарматека. 2020;27(12):38–48. https://doi.org/10.18565/pharmateca.2020.12.38-48.Mkrtumyan AM, Vorobyev SV, Volkova AR, Vorokhobina NV. Effect of Subetta on glycemic control in patients with type 2 diabetes mellitus: results of a multicenter, double-blind, placebo-controlled, randomized clinical study. Farmateka. 2020;27(12):38–48. (In Russ.) https://doi.org/10.18565/pharmateca.2020.12.38-48.Малявин АГ, Адашева ТВ, Болиева ЛЗ, Мкртумян АМ. Ранние нарушения углеводного обмена в практике врача терапевта. Современные возможности терапии. Вестник терапевта. 2024;(3). Режим доступа: https://journaltherapy.ru/statyi/ekspertnyj-sovet-rannie-narusheniyauglevodnogo-obmena-v-praktike-vracha-terapevta-sovremennyevozmozhnosti-terapii-2-ijulya-2024-goda/.Malyavin AG, Adasheva TV, Bolieva LZ, Mkrtumyan AM. Early disorders of carbohydrate metabolism in the practice of a general practitioner. Modern therapeutic options. Therapist’s Bulletin. 2024;(3). (In Russ.) Available at: https://journaltherapy.ru/statyi/ekspertnyj-sovet-rannienarusheniya-uglevodnogo-obmena-v-praktike-vracha-terapevtasovremennye-vozmozhnosti-terapii-2-ijulya-2024-goda/.Мкртумян АМ. Наблюдательная программа ВИТА: оценка эффективности и безопасности препарата Субетта в комплексной терапии сахарного диабета 2 типа у амбулаторных пациентов. Эффективная фармакотерапия. 2020;16(2):12–17. https://doi.org/10.33978/2307-3586-2020-16-2-12-17.Mkrtumyan AM. VITA Observation Program: Evaluation of the Effectiveness and Safety of the Drug Subetta in the Complex Therapy of Type 2 Diabetes in Ambulatory Patients. Effective Pharmacotherapy. 2020;16(2):12–17. (In Russ.) https://doi.org/10.33978/2307-3586-2020-16-2-12-17.

The authors declare that there are no conflicts of interest present.